ALIGNMENT HEALTHCARE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.63 USD | +26.05% |
|
+27.26% | -23.00% |
| 05-03 | UBS Adjusts Price Target on Alignment Healthcare to $6.50 From $8.50, Maintains Neutral Rating | MT |
| 05-02 | Transcript : Alignment Healthcare, Inc., Q1 2024 Earnings Call, May 02, 2024 |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,633 | 2,202 | 1,628 | 1,264 | - | - |
| Enterprise Value (EV) 1 | 2,317 | 1,954 | 1,628 | 1,270 | 1,305 | 1,260 |
| P/E ratio | -12.3 x | -14.2 x | -10.9 x | -10.3 x | -12.5 x | -20.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 2.25 x | 1.54 x | 0.89 x | 0.5 x | 0.42 x | 0.34 x |
| EV / Revenue | 1.98 x | 1.36 x | 0.89 x | 0.51 x | 0.43 x | 0.34 x |
| EV / EBITDA | -70 x | -73.1 x | -46.1 x | -1,588 x | 35.3 x | 18 x |
| EV / FCF | - | -28.2 x | - | -31.8 x | -93.6 x | -77.8 x |
| FCF Yield | - | -3.54% | - | -3.14% | -1.07% | -1.29% |
| Price to Book | - | 9.25 x | - | 11.2 x | 12.5 x | 11.1 x |
| Nbr of stocks (in thousands) | 187,242 | 187,261 | 189,100 | 190,657 | - | - |
| Reference price 2 | 14.06 | 11.76 | 8.610 | 6.630 | 6.630 | 6.630 |
| Announcement Date | 22-03-03 | 23-02-28 | 24-02-27 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 959.2 | 1,168 | 1,434 | 1,824 | 2,504 | 3,022 | 3,704 |
| EBITDA 1 | - | -33.12 | -26.72 | -35.32 | -0.8 | 36.93 | 70.09 |
| EBIT 1 | - | -49.15 | -44.2 | -56.99 | -26.55 | 23.48 | 39.37 |
| Operating Margin | - | -4.21% | -3.08% | -3.12% | -1.06% | 0.78% | 1.06% |
| Earnings before Tax (EBT) 1 | - | -195.3 | -149.3 | -148.2 | -129.8 | -114.5 | -95.27 |
| Net income 1 | - | -195.3 | -149.5 | -148 | -127.6 | -97.25 | -62.53 |
| Net margin | - | -16.72% | -10.43% | -8.12% | -5.1% | -3.22% | -1.69% |
| EPS 2 | -36.92 | -1.140 | -0.8300 | -0.7900 | -0.6443 | -0.5285 | -0.3200 |
| Free Cash Flow 1 | - | - | -69.2 | - | -39.9 | -13.95 | -16.2 |
| FCF margin | - | - | -4.83% | - | -1.59% | -0.46% | -0.44% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 21-03-03 | 22-03-03 | 23-02-28 | 24-02-27 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 298.3 | 345.5 | 366.5 | 360.3 | 361.8 | 439.2 | 462.4 | 456.7 | 465.4 | 628.6 | 624 | 618.3 | 620.2 | 757.7 | 749.1 |
| EBITDA 1 | -8.872 | -3.89 | 10.32 | -9.493 | -23.65 | -5.172 | -2.055 | -8.42 | -19.67 | -11.98 | 4.811 | 12.39 | -3.494 | -4.868 | 13.56 |
| EBIT 1 | -13.02 | -36.48 | 6.14 | -14.01 | -28.4 | -10.15 | -7.25 | -13.92 | -25.53 | -18.01 | 0.552 | 3.875 | -9.162 | -8.727 | 5.653 |
| Operating Margin | -4.37% | -10.56% | 1.68% | -3.89% | -7.85% | -2.31% | -1.57% | -3.05% | -5.49% | -2.86% | 0.09% | 0.63% | -1.48% | -1.15% | 0.75% |
| Earnings before Tax (EBT) 1 | -47.83 | -40.82 | -11.58 | -40.08 | -56.82 | -37.37 | -28.49 | -35.08 | -47.26 | -46.58 | -29.97 | -20.27 | -36.63 | -42.22 | -23.05 |
| Net income 1 | -47.83 | -40.82 | -11.58 | -40.25 | -56.9 | -37.28 | -28.48 | -35.08 | -47.21 | -46.52 | -25.33 | -18.83 | -34.7 | -35.44 | -12.6 |
| Net margin | -16.04% | -11.81% | -3.16% | -11.17% | -15.73% | -8.49% | -6.16% | -7.68% | -10.14% | -7.4% | -4.06% | -3.05% | -5.59% | -4.68% | -1.68% |
| EPS 2 | -0.2700 | -0.2300 | -0.0600 | -0.2200 | -0.3100 | -0.2000 | -0.1500 | -0.1900 | -0.2500 | -0.2500 | -0.1514 | -0.1157 | -0.1901 | -0.2127 | -0.0745 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22-03-03 | 22-05-05 | 22-08-04 | 22-11-03 | 23-02-28 | 23-05-04 | 23-08-03 | 23-11-02 | 24-02-27 | 24-05-02 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 6.15 | 41.4 | - |
| Net Cash position 1 | - | 316 | 249 | - | - | - | 3.87 |
| Leverage (Debt/EBITDA) | - | - | - | - | -7.688 x | 1.12 x | - |
| Free Cash Flow 1 | - | - | -69.2 | - | -39.9 | -14 | -16.2 |
| ROE (net income / shareholders' equity) | - | -116% | -55% | - | -105% | -100% | -90.1% |
| ROA (Net income/ Total Assets) | - | - | -23.6% | - | -17.7% | -15.1% | - |
| Assets 1 | - | - | 632.4 | - | 720.8 | 644.1 | - |
| Book Value Per Share 2 | - | - | 1.270 | - | 0.5900 | 0.5300 | 0.6000 |
| Cash Flow per Share | - | -0.4600 | -0.2500 | - | - | - | - |
| Capex 1 | - | - | 23.8 | - | 37 | 42 | 40 |
| Capex / Sales | - | - | 1.66% | - | 1.48% | 1.39% | 1.08% |
| Announcement Date | 21-03-03 | 22-03-03 | 23-02-28 | 24-02-27 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
6.63
USD
Average target price
7.682
USD
Spread / Average Target
+15.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.00% | 1.26B | |
| +11.75% | 122B | |
| +14.04% | 96.87B | |
| +0.81% | 39.92B | |
| -29.98% | 38.63B | |
| -5.99% | 19.91B | |
| -14.69% | 3.05B | |
| -27.00% | 345M |
- Stock Market
- Equities
- ALHC Stock
- Financials Alignment Healthcare, Inc.
